An Open-label, Phase 1b Study of ACP 196 in Subjects With Relapsed or Refractory de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma

Trial Profile

An Open-label, Phase 1b Study of ACP 196 in Subjects With Relapsed or Refractory de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Sep 2016

At a glance

  • Drugs Acalabrutinib (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions
  • Sponsors Acerta Pharma
  • Most Recent Events

    • 24 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 06 Nov 2015 Planned primary completion date changed from 1 Apr 2016 to 1 Jan 2017 as per ClinicalTrials.gov record.
    • 04 Aug 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top